Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$829 Mln
P/E Ratio
--
P/B Ratio
12.28
Industry P/E
--
Debt to Equity
0
ROE
-0.25 %
ROCE
-0 %
Div. Yield
0 %
Book Value
1934777.78
EPS
-0.49
CFO
$-27.05 Mln
EBITDA
$-33.68 Mln
Net Profit
$-104.98 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Harrow Health (HROW)
| -31.71 | -19.36 | -36.54 | 119.23 | 49.33 | 40.13 | 11.32 |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Harrow Health (HROW)
| 196.89 | -24.12 | 70.83 | 25.95 | -11.83 | 36.73 | 232.51 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 61.50 | 11,346.08 | 26.54 | 8.05 | |
| 64.68 | 6,636.14 | 51.14 | 23.56 | |
| 57.38 | 11,265.03 | 378.67 | 0.76 | |
| 7.69 | 9,036.23 | -- | -3.24 |
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a... chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee. Address: 1A Burton Hills Boulevard, Nashville, TN, United States, 37215 Read more
CEO & Chairman of the Board
Mr. Mark L. Baum J.D.
CEO & Chairman of the Board
Mr. Mark L. Baum J.D.
Headquarters
Nashville, TN
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Harrow Health Inc (HROW) stood at $ 388,971,000 Mln as on 31-Dec-24
The share price of Harrow Health Inc (HROW) is $22.91 (NASDAQ) as of 22-Apr-2025 16:00 EDT. Harrow Health Inc (HROW) has given a return of 49.33% in the last 3 years.
Harrow Health Inc (HROW) has a market capitalisation of $ 829 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Harrow Health Inc (HROW) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Harrow Health Inc (HROW) and enter the required number of quantities and click on buy to purchase the shares of Harrow Health Inc (HROW).
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee. Address: 1A Burton Hills Boulevard, Nashville, TN, United States, 37215
The CEO & director of Mr. Mark L. Baum J.D.. is Harrow Health Inc (HROW), and CFO & Sr. VP is Mr. Mark L. Baum J.D..
There is no promoter pledging in Harrow Health Inc (HROW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Harrow Health Inc. (HROW) | Ratios |
|---|---|
|
Return on equity(%)
|
-0
|
|
Operating margin(%)
|
4.42
|
|
Net Margin(%)
|
-0
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Harrow Health Inc (HROW) was $0 Mln.
$-0.33
(
